Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand

LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi^® saypha^® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product in the Obagi^® saypha^® collection under the Obagi Medical brand. This approval marks Waldencast’s entry into the U.S. HA dermal filler market through Obagi Medical and reinforces the Company’s ambition to become a multi-product innovator in aesthetics, doubling Obagi Medical’s total addressable market to approximately $4.2 billion by 2029.¹

Read more at globenewswire.com